| Bevacizumab in the treatment of metastatic breast cancer: three case reports. | |
| | |
MedLine Citation:
|
PMID: 21490480 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Case reports are presented for three patients with metastatic breast cancer who received first-line treatment with bevacizumab in combination with taxanes in clinical trials. Two patients showed peak reductions in lesion size of 49 and 70%, respectively. In one patient, subsequent treatment with bevacizumab in combination with capecitabine [Xeloda (after discontinuation of paclitaxel due to asthenia)] yielded peak reductions in target lesion size of 78%. One patient experienced a progression-free survival time of 16 months. In all three patients, bevacizumab was well tolerated and mostly displayed only mild toxicities. |
| | |
Authors:
|
Ana Ferreira; Cláudia Vieira; Ana Rodrigues; Deolinda Pereira; Helena Rodrigues; Cristina Dávila; Sandra Bento |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Current opinion in oncology Volume: 23 Suppl ISSN: 1531-703X ISO Abbreviation: Curr Opin Oncol Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-04-14 Completed Date: 2011-06-21 Revised Date: 2013-05-28 |
Medline Journal Info:
|
Nlm Unique ID: 9007265 Medline TA: Curr Opin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: S11-9 Citation Subset: IM |
Affiliation:
|
Hospital Distrital de Santarém, Avenida Bernardo Santereno, 2000 Santarém, Portugal. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
administration & dosage*,
therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols / adverse effects*, therapeutic use* Bone Neoplasms / radiotherapy, secondary, surgery Breast Neoplasms / drug therapy*, pathology, radiotherapy, surgery Carcinoma in Situ / drug therapy*, pathology, radiotherapy, surgery Carcinoma, Ductal / drug therapy*, pathology, radiotherapy, secondary*, surgery Combined Modality Therapy Deoxycytidine / administration & dosage, adverse effects, analogs & derivatives Disease-Free Survival Female Fluorouracil / administration & dosage, adverse effects, analogs & derivatives Humans Kidney Neoplasms / radiotherapy, secondary, surgery Liver Neoplasms / radiotherapy, secondary, surgery Lung Neoplasms / radiotherapy, secondary, surgery Lymphatic Metastasis Paclitaxel / adverse effects Survival Analysis Taxoids / administration & dosage Treatment Outcome Vascular Endothelial Growth Factor A / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Taxoids; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab; 33069-62-4/Paclitaxel; 51-21-8/Fluorouracil; 6804DJ8Z9U/capecitabine; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of estimated glomerular filtration rate reporting on nephrology referrals: a review of the li...
Next Document: Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanc...